5JA1 Stock Overview
A pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Sprint Bioscience AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.11 |
| 52 Week High | SEK 0.17 |
| 52 Week Low | SEK 0.051 |
| Beta | 0.36 |
| 11 Month Change | -16.92% |
| 3 Month Change | 10.44% |
| 1 Year Change | -31.46% |
| 33 Year Change | -76.62% |
| 5 Year Change | n/a |
| Change since IPO | -87.21% |
Recent News & Updates
Recent updates
Shareholder Returns
| 5JA1 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0.4% | 0.8% | -1.3% |
| 1Y | -31.5% | -17.5% | 7.4% |
Return vs Industry: 5JA1 underperformed the German Biotechs industry which returned -16.7% over the past year.
Return vs Market: 5JA1 underperformed the German Market which returned 7.1% over the past year.
Price Volatility
| 5JA1 volatility | |
|---|---|
| 5JA1 Average Weekly Movement | 18.9% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 5JA1's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 5JA1's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 36 | Johan Emilsson | www.sprintbioscience.com |
Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. It develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; and PETRA01, a drug candidate for the treatment of cancer. The company also focuses on research of products for the treatment of tumor metabolism, nash, and diabetes.
Sprint Bioscience AB (publ) Fundamentals Summary
| 5JA1 fundamental statistics | |
|---|---|
| Market cap | €9.17m |
| Earnings (TTM) | -€1.65m |
| Revenue (TTM) | €5.30m |
1.7x
P/S Ratio-5.6x
P/E RatioIs 5JA1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 5JA1 income statement (TTM) | |
|---|---|
| Revenue | SEK 61.45m |
| Cost of Revenue | SEK 24.98m |
| Gross Profit | SEK 36.47m |
| Other Expenses | SEK 55.58m |
| Earnings | -SEK 19.11m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.27 |
| Gross Margin | 59.35% |
| Net Profit Margin | -31.10% |
| Debt/Equity Ratio | 0% |
How did 5JA1 perform over the long term?
See historical performance and comparison